Werner Van den Eynde, MD, a specialist physician in pharmaceutical medicine, has joined NDA Group to head-up the NDA Advisory Board.
Dr. Van den Eynde has extensive international pharmaceutical experience, holding senior positions within Chemo – Exeltis, GE Healthcare, Abbott and Solvay Pharmaceuticals. As Vice President of NDA Advisory Services Ltd, Dr. Van den Eynde will manage the operations, strategy and development of the NDA Advisory Board, including business development, sales, marketing and service development.
The NDA Advisory Board provide strategic advice and unbiased second opinions to pharmaceutical clients during part of, or the complete end-to-end drug development life cycle. This also includes support and advice during interaction with regulatory agencies, be it at scientific advice, during review of a marketing authorisation application or at any stage post-authorisation.
“The NDA Advisory Board is one of a kind – no other professional body comes as close to reflecting the current opinions and practices of the world’s regulatory and reimbursement agencies. I am very excited to welcome Werner Van den Eynde on board to lead the NDA Advisory Board into the future. With his experience in drug development, following the process from many perspectives, he will be able to add tremendous value to clients in all stages of development, as well as create tailored teams and services of great benefit to the drug developing industry,” commented Johan Strömquist, CEO of NDA Group.
Dr. Van den Eynde is joining NDA from Chemo – Exeltis where he was the head of R&D, Regulatory Affairs and Pharmacovigilance. Before that Dr. Van den Eynde worked as Chief Medical Officer at GE Healthcare and prior to this as Executive Vice President for global medical affairs at Solvay Pharmaceuticals.
“It is with great pride that I take up the position as Vice President for the NDA Advisory Board. NDA is the perfect platform for anyone who wants to have a great positive impact on drug development across the world and the excellent reputation of the NDA Advisory Board is wide spread. Building on an almost twenty year tradition of objective and unbiased advice to drug developing companies I’m very motivated to continue the NDA success story and expand the NDA Advisory Board to meet the future demands that science, technology and the regulatory environment put on companies developing important therapies for patients in need,” said Dr. Van den Eynde.
Dr. Van den Eynde takes up his position at NDA in August.